跳至主要内容
临床试验/NCT01585857
NCT01585857已完成1 期

A Phase I, Prospective, Bi-centric,Single -Arm, Open-label, Dose-escalating Clinical Trial to Evaluate the Safety of a Single Injection of Autologous Adipose Derived Mesenchymal Stromal Cells in the Treatment of Severe Osteoarthritis of the Knee Joint

University Hospital, Montpellier4 个研究点 分布在 2 个国家目标入组 18 人开始时间: 2012年4月最近更新:
适应症

试验速览

阶段
1 期
状态
已完成
入组人数
18
试验地点
4
主要终点
Recording of Serious Adverse Events

研究概览

简要总结

Primary:

To study the safety of a single injection of autologous adipose derived mesenchymal stromal cells (ASCs) on patients with moderate or severe osteoarthritis of the knee (OA).

Secondary:

To study the efficacy of a single injection of autologous adipose derived mesenchymal stromal cells on patients with moderate or severe osteoarthritis of the knee (OA).

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
50 Years 至 75 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • OA diagnosis should fulfil the criteria of the American College of Rheumatology (ACR) with moderate or severe medial and/ or external femorotibial knee osteoarthritis (OA) (stage 3 or 4) and indication total knee arthroplasty.

排除标准

  • Any disease or medication affecting the bone or cartilage metabolism, including corticoids.

结局指标

主要结局

Recording of Serious Adverse Events

时间窗: during 365 days following injection

Adverse events will be described with respect to seriousness, intensity, relationship to treatment, action taken and outcome of the adverse event.

次要结局

  • Functional status of the knee(during 365 days following injection)
  • Evaluation of Quality of life(during 365 days following injection)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (4)

Loading locations...

相似试验